By Will Feuer
Celularity Chief Executive Robert Hariri said the biotechnology company expects to report 2023 revenue that is 23% to 27% higher than the previous year.
For the fourth quarter, the company’s sales are on pace to rise 176% to 193%. He said in a letter to shareholders that the company would soon report its forecasts for first-quarter and 2024 sales.
He said the company is focusing on maintaining and building on its fourth-quarter sales momentum, as well as advancing its new product candidates. He said the company is also looking to expand outside of its core wound-care and surgical-applications businesses.
Write to Will Feuer at [email protected]
Read the full article here
